8. nov. 2013
Dissertation and trial lecture: Jo Waaler - Kreftbehandling og kreftbiologi
GSK3β as an integrator of multiple signaling pathways during normal development and cancer
8th of November 09.15, Seminarrom 1 B2.U001, Oslo universitetssykehus HF, Rikshospitalet
8th of November 09.15, Seminarrom 1 B2.U001, Oslo universitetssykehus HF, Rikshospitalet
M.Sc. Jo Waaler: Development of specific tankyrase inhibitors for attenuating canonical Wnt/β-catenin signaling.
8th of November 11.15, Seminarrom 1 B2.U001, Oslo universitetssykehus HF, Rikshospitalet
14-15 October 2013
The 10th Annual Norwegian Stem Cell Networking Meeting, Oslo
The 10th Annual Norwegian Stem Cell Networking Meeting will be held on October 14-15
For more information visit NCS
In this prospective study, covered in "Clinical significance of disseminated tumour cells in non-small cell lung cancer", Mælandsmo et al. have investigated the presence of DTCs in the bone marrow collected from 296 patients with stages I–IIIA NSCLC undergoing curatively intended surgery, using both IMS and ICC. In addition, 81 bone marrow samples from healthy volunteers were investigated using IMS.
They have compared the results from the two methods, investigated the associations with clinicopathological parameters and examined the prognostic impact of the presence of DTCs.
This paper has been pre-published in the British Journal of Cancer's advanced online publication 13th of August 2013.
14th - 16th July, 2013
Wnt Symposium 2013, Heidelberg
Leonardo A. Meza-Zepeda head of project group "Translational Genomics"
Senior Scientist Leonardo A. Meza-Zepeda from Ola Myklebost's group "Molecular characterization of mesenchymal cancer" has become head of his own research group called "Translational Genomics". This research group is divided into to focus areas; Genetic and epigenetic networks of mesenchymal stem cell differentiation and Integrated analysis of genetic and epigenetic changes of human sarcomas.
By identifying and characterising the specific transcriptional programs active during differentiation of mesenchymal stem cells "Genetic and epigenetic networks of mesenchymal stem cell differentiation" work towards a better understanding of the blance between stemness and differentiation and its deregulation in cancer.
Integrated analysis of genetic and epigenetic changes of human sarcomas togheter with different EuroBoNet (European Network of Excellence for Bone Tumours) preclinical osteosarcoma panels (cell lines and xenografts) focus on unveiling pathways and transcriptional and gene networks in osteosarcomas (bone tumours) and the way these are controlled.
The analysis of Leonardo A. Meza-Zepeda's group has already identified the importance of epigenetic silencing in controlling gene expression.
For more information see the homepage for "Translational Genomics"
A new study looking at the genomes of more than 13,000 men identified four new genetic variants associated with an increased risk of testicular cancer, the most commonly diagnosed type in young men today. The findings from this first-of-its-kind meta-analysis were reported online May 12 in Nature Genetics by researchers in Norway and the United States.
This discovery could ultimately help researchers better understand which men are at high risk for for texticular cancer and allow for early detection or prevention of the disease.
“As we continue to cast a wider net, we identify additional genetic risk factors, which point to new mechanisms for disease,” said Katherine L. Nathanson, MD, associate professor in the division of Translational Medicine and Human Genetics within the department of Medicine at the University of Pennsylvania. “Certain chromosomal regions, what we call loci, are tied into testicular cancer susceptibility, and represent a promising path to stratifying patients into risk groups—for a disease we know is highly heritable.” - writes Penn Medicine
Despite being a heritable disease, testicular cancer is actually relatively rare. The incidence rates have however doubled in the past 40 years.
May 2013 (Norwegian only)
Forskere hos PCI Biotech imponerer
PCI's banebrytende forskning på fotokjemisk internalisering har vakt oppsikt i nasjonal media.
"PCI-metoden (photochemical internalization) ble oppfunnet i 1995 av den norske forskeren Kristian Berg.
Kristian Berg er i dag professor ved Seksjon for strålingsbiologi, Institutt for kreftforskning på Senter for forskningsdrevet innovasjon. Pål Selbo og Monica Bostad arbeider i hans forskningsgruppe.
Metoden og det fotosensibiliserende stoffet Amphinex kan også brukes i andre sammenhenger enn beskrevet i denne artikkelen.
Blant annet har forskergruppen vist med museforsøk at PCI kan frigjøre et antibiotikum, bleomycin, som også bekjemper kreftceller.
Denne metoden er nå under utprøving i et Fase II-studium på fem anerkjente kreftsykehus i Europa.
Excellent Researcher Award to Dr. Harald Stenmark
Nine research awards were distributed to scientists from Oslo University Hospital on Friday, April 26th. The prizes were given out by Bjørn Erikstein, managing director at the hospital during a ceremony taking place at Rikshospitalet, Gaustad.
Dr. Harald Stenmark was the first ever to recieve the "Excellent Researcher Award". The award prize is a total of 300 000 NOK.
Also two "Early Career Awards" were presented, each amounting to 150 000 NOK. Guro Elisabeth Lind and Tom Hemming Karlsen received these prizes.
In addition six excellent research articles were awarded 50 000 NOK each.
For more information see Oslo University Hospital webpage or
As a proof-of-concept, Bostad et al., demonstrate for the first time that PCI can be used to deliver therapeutics that target cancer stem cells (CSCs)
The manuscript first-authored by Monica Bostad from Kristian Berg's group at the Department of Radiation Biology - entitled “Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties” was recently published in the highly recognized drug delivery periodical "Journal of Controlled Release" (5 year impact factor: 7.529, NIFU step level 2).
As a proof-of-concept, Bostad et al., demonstrate for the first time that PCI can be used to deliver therapeutics that target cancer stem cells (CSCs).
Work on selective tankyrase inhibitor from Krauss and collaborators highlighted as cover story in Sci-Bx
A research team from SFI-CAST Innovation Center at the Oslo University Hospital, led by Stefan Krauss, has developed a highly selective tankyrase inhibitor.
Tankyrase is a druggable target in the otherwise hard-to-hit Wnt signaling pathway and has implications in colon cancer, pancreas adenocarcinoma, ovary cancer, lung cancer and other solid tumors. The tankyrase inhibitor may open a new therapeutic approach.
Structural-relation activity data, crystallography and pharmacokinetics were reported in the Journal of Medicinal Chemistry while target validation data including mouse efficacy data, in collaboration with Roche's Genentech Inc. unit, were reported in Cancer Research. The work is highlighted as the cover story in SciBx, a weekly publication that provide analysis of the scientific content and commercial potential of the most important translational research papers with the potential to transform human therapeutics and diagnostics.
Drs Sigrid Marie Kraggerud, Christina Høi-Hansen and Sharmini Alagaratnam publish in Endrocrine Reviews, the highest ranked journal in the category of Endocrinology and metabolism with IF of 19.9.
In a comprehensive review the Lothe-group together with colleagues from University of Copenhagen (Rigshospitalet), Dr. Ewa Rajpert-De Meyts -group, revisit the total literature on molecular biology of germ cell tumors of the ovary. The molecular features of the mOGCTs underline their similarity to pluripotent precursor cells (primordial germ cells, PGCs) and other stem cells. This similarity combined with the process of ovary development, explain why mOGCTs present so early in life, and with greater histological complexity, than most somatic solid tumors.
Sharmini Alagaratnam has worked both for the Norwegian Research Council’s Program for Stem Cell Research, and the Cancer Stem Cell Innovation Center CAST, on a project to identify malignancy genes in stem cells. Part of this work has recently been published in the journal Stem Cells and Development, and represents the first direct comparison of gene expression in embryonic stem cells and their malignant counterpart, embryonal carcinoma, cultured under identical conditions. This was a collaborative study between the Molecular Genetics and the Genome Biology groups at the Department of Cancer Prevention.
A gene signature distinguishing the two cell types was identified, which included a number of cancer relevant and pluripotency genes. NR5A2 is an especially intriguing candidate given its role in the WNT-signalling pathway, which is often disrupted in cancer, and particularly so in colorectal cancer.
SFI-CAST Annual Report 2012
The SFI-CAST annual report is available
Most colorectal cancers (CRC) are initiated by mutations of APC, leading to increased β-catenin-mediated signaling. However continued requirement of Wnt/β-catenin signaling for tumor progression in the context of acquired KRAS and other mutations is less well established.
To attenuate Wnt/β-catenin signaling in tumors, memebers of Stefan Krauss' group have developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β-catenin destabilization.
Read more about this subject in "A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth" published in the latest issue of Cancer Research, 15th of March 2013.